Stockscreener 앱 받기
2.93
2.09%
0.06
시간 외 거래:
2.99
0.06
+2.05%
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript - AOL.ca
ETFs Investing in Fortress Biotech, Inc. Stocks - TradingView
Fortress Biotech (FBIO) Slips 1.68% to $2.93 as Small-Cap Biotech Faces PressureBollinger Squeeze - vinanet.vn
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Fortress Biotech (FBIO) Pulls Back 3% as Shares Approach Key $2.75 SupportFear Greed Index - vinanet.vn
Fortress Biotech, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Fortress Biotech earnings beat by $0.11, revenue fell short of estimates - Investing.com Canada
Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Fortress Biotech: Q2 Earnings Snapshot - marketscreener.com
Fortress Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary - TradingView
Fortress Biotech (NASDAQ: FBIO) gains $158.9M from voucher sale and boosts cash - Stock Titan
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Q2 Earnings Call Highlights - MarketBeat
FBIO Looks 125.0% Overvalued on GF Value™ Ahead of Q2 Earnings - GuruFocus
Fortress Biotech (FBIO) Q2 2026 Earnings Call - finance.biggo.com
Fortress Biotech Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
The Technical Signals Behind (FBIOP) That Institutions Follow - Stock Traders Daily
FBIO Q1 2026 Earnings: Significant EPS Miss Triggers Modest Stock DeclineDiluted EPS Report - vinanet.vn
Law firm investigates Fortress Biotech for poss... - Pluang
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after market close on August 12. - 富途牛牛
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO) - PR Newswire
Fortress Biotech (FBIO) to Release Earnings on Thursday - MarketBeat
Best Cheap Stocks Under $10 with High Return Potential (August 2026) - Investing.com
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
FBIOP Q1 2026 Earnings: Significant EPS Shortfall Amid Challenging QuarterEarnings Surprise Report - vinanet.vn
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing - marketscreener.com
Fortress Biotech Preferred Stock (FBIOP) Edges Lower Amid Quiet Trading – Key Support and Resistance Levels in FocusDemand Zone - dars.gov.et
Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fortress Biotech Inc (FBIO) Balance Sheet - TradingKey
Fortress Biotech Inc (FBIO) Institutional Confidence - TradingKey
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing - The Manila Times
FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090 - TradingKey
Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Journey Medical Corp (DERM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Income Statement - TradingKey
Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy - Seeking Alpha
Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume TradingMerger Arbitrage - dars.gov.et
Technical Reactions to FBIOP Trends in Macro Strategies - Stock Traders Daily
$3.74 | Fortress Biotech, Inc. Common Stock (FBIO) Stock Price Today - Binance
Fortress Biotech Achieves 73.6% Return in the Stock Market Over Past Year - MarketsMojo
MSN Money - MSN
FBIOP Preferred Stock Slips 1.15% as Perpetual Preferred Faces ResistanceMcClellan Oscillator - vinanet.vn
CNB0 Bond Coupon Profile — Rate & Payments - TradingView
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion - BioBuzz
Fortress Biotech Preferred Stock (FBIOP) Edges Lower as Support Levels Are TestedChaikin Flow - dars.gov.et
Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesEarnings Weakness Phase - dars.gov.et
Fortress Biotech (FBIO) Edges Lower Amid Quiet Trading, Holds Above Key SupportWeekly Profile - DonanımHaber
Fortress Biotech highlights its biotech portfolio strategy as a Nasdaq-listed micro-cap - Ad Hoc News
Mustang Bio (MBIO) Proxy Filing Summary - Quartr
Mustang Bio (MBIO) Registration Filing Summary - Quartr
Fortress Biotech Preferred Shares (FBIOP) Slide 1.98% as Support Test ApproachesPut Flow Alert - dars.gov.et
Fortress Biotech focuses on specialty pharma growth and licensing model - Ad Hoc News
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 B - GuruFocus
Fortress Biotech (FBIO) Slides 2.14% as Selling Pressure Persists Near Support LevelHigh Dividend Factor - dars.gov.et
0.00%
3.22%
자본화:
|
볼륨(24시간):